NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
NorthSea Therapeutics to Present ICONA Phase 2b Data as an Oral Late-breaker Session at the 2023 AASLD Liver Meeting<
10 Nov 2023

NorthSea Therapeutics to Present ICONA Phase 2b Data as an Oral Late-breaker Session at the 2023 AASLD Liver Meeting

Study results identify NASH patients with Type 2 Diabetes as the key target population for Icosabutate therapy
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights<
09 Nov 2023

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical Trial
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases<
07 Nov 2023

Kynexis Launched to Advance Precision Therapeutics for Brain Diseases

Company co-founded by Forbion and Ysios Capital
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update<
07 Nov 2023

Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023.
Aura Biosciences Announces Proposed Public Offering of Common Stock<
06 Nov 2023

Aura Biosciences Announces Proposed Public Offering of Common Stock

Aura also intends to grant the underwriters a 30-day option to purchase up to an additional 15%

Aura Biosciences Announces Pricing of Public Offering of Common Stock<
06 Nov 2023

Aura Biosciences Announces Pricing of Public Offering of Common Stock

The gross proceeds from the offering to Aura are expected to be $99.0 million
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma<
06 Nov 2023

Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma

Positive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing Phase 2 Clinical Trial

Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting<
02 Nov 2023

Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting

Target-HTN trial results support the transition to late-stage development of lorundrostat as a treatment for uncontrolled and resistant hypertension.

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023<
31 Oct 2023

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Presented at the upcoming American Academy of Ophthalmology (AAO) 2023 Annual Meeting being held November 3-6, 2023, in San Francisco.
NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease<
17 Oct 2023

NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease

RPD designation underscores critical need for novel therapies to address IFALD

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка